Cargando…

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease

Background: The value of aspirin for primary prevention continues to be debated. Data showing whether aspirin use for primary prevention adheres to established guidelines in real world practice are sparse. Methods: A total of 13,104 patients without cardiovascular diseases (CVD) were selected from t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yinong, Yin, Chun, Li, Qing, Yu, Luyao, Zhu, Longyang, Hu, Dayi, Sun, Yihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446611/ https://www.ncbi.nlm.nih.gov/pubmed/34540919 http://dx.doi.org/10.3389/fcvm.2021.720113

Ejemplares similares

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19
por: Diaz, Temistocles, et al.
Publicado: (2020)

Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients
por: Wang, Zhe, et al.
Publicado: (2022)

Circadian Rhythm of Cardiovascular Disease: The Potential of Chronotherapy With Aspirin
por: Buurma, Marleen, et al.
Publicado: (2019)

Association between hypertriglyceridemic-waist phenotype and cardiovascular disease: A cohort study and meta-analysis
por: Zheng, Xiaowei, et al.
Publicado: (2022)

Aspirin for the prevention of preeclampsia: A systematic review and meta-analysis of randomized controlled studies
por: Wang, Yixiao, et al.
Publicado: (2022)

Low-dose aspirin in the prevention of preeclampsia in twin pregnancies: A real-world study
por: Zhou, Qiongjie, et al.
Publicado: (2023)

Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
por: Byrne, Paula, et al.
Publicado: (2019)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Metabolic disorders and risk of cardiovascular diseases: a two-sample mendelian randomization study
por: Wang, Zhe, et al.
Publicado: (2023)

The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
por: van Gils, Paul F, et al.
Publicado: (2011)

Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study
por: Lee, Meng, et al.
Publicado: (2014)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
por: Khan, Hamzah, et al.
Publicado: (2022)

Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews
por: Collins, Dylan R J, et al.
Publicado: (2017)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
por: Kandil, Omneya A., et al.
Publicado: (2022)

High sensitivity troponins: A potential biomarkers of cardiovascular risk for primary prevention
por: Leite, Luis, et al.
Publicado: (2022)

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
por: Toth, Peter P., et al.
Publicado: (2023)

Primary and secondary cardiovascular disease prevention interventions targeting lifestyle risk factors in women: A systematic review and meta-analysis
por: Slater, Kaylee, et al.
Publicado: (2022)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis
por: Liu, Di, et al.
Publicado: (2023)

Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: protocol for an overview of systematic reviews
por: Studzin´ski, Krzysztof, et al.
Publicado: (2017)

Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial
por: Chen, Mu, et al.
Publicado: (2021)

Aspirin misuse: a case report
por: Goldrich, David, et al.
Publicado: (2019)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Low-molecular-weight heparin in addition to low-dose aspirin for preventing preeclampsia and its complications: A systematic review and meta-analysis
por: Zheng, Li, et al.
Publicado: (2022)

Text messages for primary prevention of cardiovascular disease: the TextMe2 randomised controlled trial protocol
por: Klimis, Harry, et al.
Publicado: (2020)

Renal safety evaluation of aspirin plus edaravone in patients with ischaemic stroke: a retrospective cohort study
por: Yang, Hui-qin, et al.
Publicado: (2022)

Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease
por: Byrne, Paula, et al.
Publicado: (2018)

Protocol for the evaluation of a pilot implementation of essential interventions for the prevention of cardiovascular diseases in primary healthcare in the Republic of Moldova
por: Collins, Dylan, et al.
Publicado: (2019)

Association Between Lipids and Arterial Stiffness for Primary Cardiovascular Prevention in a General Middle-Aged European Population
por: Vallée, Alexandre
Publicado: (2022)

Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
por: Shah, Aditya, et al.
Publicado: (2022)

Karma of Cardiovascular Disease Risk Factors for Prevention and Management of Major Cardiovascular Events in the Context of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
por: Crisan, Liliana, et al.
Publicado: (2019)

Editorial: Physical activity and exercise for the prevention and management of cardiovascular risk and cardiovascular disease
por: Volterrani, Maurizio, et al.
Publicado: (2023)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Editorial: Insights in cardiovascular epidemiology and prevention: 2022
por: Lin, Gen-Min
Publicado: (2023)

Platelet Aggregation Before Aspirin Initiation in Pediatric Patients With Congenital Heart Disease at High Risk of Thrombosis
por: Lu, Zhong-Yuan, et al.
Publicado: (2022)

Effect of aspirin in takotsubo syndrome: protocol of a systematic review and meta-analysis
por: Lin, Jinhai, et al.
Publicado: (2021)

Longitudinal changes in blood pressure and fasting plasma glucose among 5,398 primary care patients with concomitant hypertension and diabetes: An observational study and implications for community-based cardiovascular prevention
por: Yu, Xiao, et al.
Publicado: (2023)

Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism
por: Lin, Xiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_55f9r9kug6e33et1hc4mn76brv